These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 21511692

  • 1. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.
    Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.
    Mult Scler; 2011 Sep; 17(9):1074-8. PubMed ID: 21511692
    [Abstract] [Full Text] [Related]

  • 2. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 3. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
    Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.
    J Neurol Sci; 2012 Mar 15; 314(1-2):138-42. PubMed ID: 22050952
    [Abstract] [Full Text] [Related]

  • 4. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Neurology; 2007 Oct 02; 69(14):1391-403. PubMed ID: 17761550
    [Abstract] [Full Text] [Related]

  • 5. Natalizumab for relapsing-remitting multiple sclerosis.
    Horga A, Tintoré M.
    Neurologia; 2011 Oct 02; 26(6):357-68. PubMed ID: 21193250
    [Abstract] [Full Text] [Related]

  • 6. Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
    Oliver B, Fernández O, Orpez T, Alvarenga MP, Pinto-Medel MJ, Guerrero M, León A, López-Madrona JC, Maldonado-Sánchez R, García-León JA, Luque G, Fernández V, Leyva L.
    Mult Scler; 2011 Mar 02; 17(3):368-71. PubMed ID: 21177326
    [Abstract] [Full Text] [Related]

  • 7. Prediction of antibody persistency from antibody titres to natalizumab.
    Jensen PE, Koch-Henriksen N, Sellebjerg F, Sørensen PS.
    Mult Scler; 2012 Oct 02; 18(10):1493-9. PubMed ID: 22454098
    [Abstract] [Full Text] [Related]

  • 8. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
    Prosperini L, Giannì C, Barletta V, Mancinelli C, Fubelli F, Borriello G, Pozzilli C.
    J Neurol Sci; 2012 Dec 15; 323(1-2):104-12. PubMed ID: 23006974
    [Abstract] [Full Text] [Related]

  • 9. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
    Pilz G, Harrer A, Oppermann K, Wipfler P, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.
    Mult Scler; 2012 Apr 15; 18(4):506-9. PubMed ID: 21965415
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 15; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 11. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
    Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.
    Mult Scler; 2013 Apr 15; 19(5):593-600. PubMed ID: 22992450
    [Abstract] [Full Text] [Related]

  • 12. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
    Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, Huemer M, Kunz A, Golaszewski S, Staffen W, Ladurner G, Kraus J.
    Mult Scler; 2011 Jan 15; 17(1):16-23. PubMed ID: 20937631
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 15; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 14. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE.
    Mult Scler; 2011 Aug 15; 17(8):970-9. PubMed ID: 21421809
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B, Aboul-Enein F, Rostasy K, Milos RI, Steiner I, Penzien J, Hellwig K, Pitarokoili K, Storm van's Gravesande K, Karenfort M, Blaschek A, Meyer A, Seidl R, Debelic D, Vass K, Prayer D, Kristoferitsch W, Bayas A.
    JAMA Neurol; 2013 Apr 15; 70(4):469-75. PubMed ID: 23420110
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.
    Arnal-Garcia C, García-Montero MR, Málaga I, Millán-Pascual J, Oliva-Nacarino P, Ramió-Torrentà L, Oreja-Guevara C.
    Eur J Paediatr Neurol; 2013 Jan 15; 17(1):50-4. PubMed ID: 23021975
    [Abstract] [Full Text] [Related]

  • 17. [Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].
    Tasset I, Aguera E, Gascon F, Giraldo AI, Salcedo M, Cruz AH, Sanchez F, Tunez I.
    Rev Neurol; 2012 Apr 16; 54(8):449-52. PubMed ID: 22492096
    [Abstract] [Full Text] [Related]

  • 18. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 16; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 19. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.
    Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, Guiziou C, Kassiotis P, Lallement F, Laplaud D, Diraison P, Rouhart F, Sartori E, Wardi R, Wiertlewski S, Edan G.
    J Neurol Sci; 2011 Sep 15; 308(1-2):98-102. PubMed ID: 21665227
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.